Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsFidelis Care oncology prior auth policy | OpenPaye…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentFidelis CarePolicy N/A

    Oncology medications and supportive agents prior authorization

    Customize your policy alerts

    Sign up for all Fidelis Care policy alerts

    Know when Fidelis Care releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior review/authorization requirements for oncology medications and supportive agents for Medicare - Wellcare by Fidelis Care members and specifies agent lists, biosimilar preferences, and submission instructions for participating and non-participating providers.

    Policy Summary
    PayerFidelis Care
    PolicyOncology medications and supportive agents prior authorization
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit the entire oncology regimen to Evolent for review; omissions may result in denial.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    100+listed HCPCS/CPT/J-codes requiring review
    2025-09-01pharmacy benefit effective date
    Multiplepreferred biosimilar agents named
    All agesapplies to

    Coverage & Authorization Criteria

    Prior Review / Authorization Requirement

    Covered when ALL of the following are met:

    Prior review required: The listed oncology medications and supportive agents require review by Evolent before being dispensed at a pharmacy or administered in a physician's office, outpatient hospital, or ambulatory setting for members of all ages.

    Includes medical and pharmacy benefit drugs listed by HCPCS/J/Q codes; participating providers must submit via Evolent web portal or phone; non-participating providers submit to the plan via fax (updated fax 1-844-235-5090).

    Complete regimen submission: The complete oncology regimen must be submitted to Evolent regardless of individual prior authorization requirements; omissions of regimen components may result in denial.

    Submit full regimen for review (see portal or phone submission instructions).

    Do NOT submit the following request types to Evolent; these items are considered out-of-scope for prior review under this oncology medication policy: antibiotics; bone marrow, stem cell transplants, and CAR-T cell therapy; controlled substances (e.g., morphine); equipment requests such as infusion pumps; genetic laboratory testing and laboratory services; hemophilia drugs; inpatient drug requests; inpatient radiation and chemotherapy treatments; iron preparations; radiopharmaceuticals; surgeries/surgical procedures; sickle cell diagnoses and therapies; and immune globulins.

    Relevant Codes and Benefit Lists

    Oncology HCPCS/J/Q codes requiring reviewHCPCSCovered
    C9174DATOPOTAMAB DERUXTECAN-DLNK (DATROWAY)
    C9175TREOSULFAN (GRAFAPEX)
    C9293GLUCARPIDASE
    J0185APREPITANT INJ
    J0207AMIFOSTINE INJ
    J0208SODIUM THIOSULFATE
    J0594BUSULFAN INJ
    J0641LEVOLEUCOVORIN INJ (variant)
    J0642LEVOLEUCOVORIN INJ (variant)
    J0870IMETELSTAT (RYTELO) J0870 mapping
    1–10 of 29
    1/3
    Oral oncology agents (pharmacy benefit list) — effective 9/1/2025HCPCS | mixedCovered
    J8999Miscellaneous oral oncology agents listed (many specific drugs mapped to J8999)
    J7520SIROLIMUS ORAL
    J7527EVEROLIMUS ORAL
    J8501APREPITANT ORAL

    Provider Submission & Authorization Actions

    Prior Authorization

    Prior authorization required for listed oncology agents

    The listed oncology medications and supportive agents identified by HCPCS/J/Q codes require review by Evolent before being dispensed at a pharmacy or administered in a physician's office, outpatient hospital, or ambulatory setting for members of all ages.

    • Includes medical and pharmacy benefit drugs listed by code.
    Step Therapy

    Pharmacy benefit review effective 9/1/2025

    Certain oral oncology agents will require review by Evolent and will be available via the pharmacy benefit effective 9/1/2025 for Wellcare by Fidelis Care members.

    • Examples include oral agents listed under J7520, J7527, J8501, J8530, J8565, J8600, J8655, J8670, multiple J8999 mappings (e.g., abemaciclib, abiraterone, acalabrutinib).

    Background & Scope

    This document is administrative and coverage-focused. Providers must submit the entire oncology regimen to Evolent for review regardless of whether individual agents require prior authorization; omitting parts of the regimen may result in a denial. Preferred biosimilar agents are named for certain drug classes (erythropoiesis-stimulating agents, trastuzumab, bevacizumab, hematopoietic agents) and should still be submitted to Evolent for review per normal submission procedures.

    Site of Care Applicability

    Note

    Site-of-care review required (office, infusion center, hospital outpatient, pharmacy)

    Drugs administered in a physician's office, infusion center, hospital outpatient or dispensed at a pharmacy require review by Evolent prior to administration or dispensing.

    • This applies to ambulatory settings and all members of all ages.

    Biosimilar & Product Preferences

    Billing Rule

    Erythropoiesis‑stimulating agent preference: Retacrit (Epogen alternative)

    For erythropoiesis‑stimulating agents, Retacrit is the preferred medical‑benefit agent; if Retacrit is unavailable due to shortage, Epogen is listed as the alternative. Procrit is the pharmacy‑benefit preference.

    • Medical benefit: Retacrit (if unavailable due to shortage: Epogen).
    • Pharmacy benefit: Procrit.
    Billing Rule

    Trastuzumab biosimilar preference — Trazimera (medical benefit)

    Trastuzumab preferred medical‑benefit biosimilar is Trazimera; several trastuzumab products are listed on the pharmacy benefit and should be submitted to Evolent for review.

    • Medical benefit preferred: Trazimera.
    Policy Summary
    PayerFidelis Care
    PolicyOncology medications and supportive agents prior authorization
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateN/A
    Next Review DateN/A
    Key ActionSubmit the entire oncology regimen to Evolent for review; omissions may result in denial.
    SourceLink
    On This Page
    Coverage & Authorization CriteriaRelevant Codes and Benefit ListsProvider Submission & Authorization ActionsBackground & ScopeSite of Care ApplicabilityBiosimilar & Product Preferences
    Documentation Required

    Submission instructions — portal, phone, or plan fax

    Submit requests to Evolent with the entire oncology regimen; participating providers may use Evolent's web portal or call the Evolent review line, while non‑participating providers must submit to the plan via fax.

    • Participating providers: my.newcenturyhealth.com or call 1-888-999-7713, option 1.
    • Non‑participating providers: submit to the plan via fax (updated fax 1-844-235-5090).
    Denial Risk

    Complete regimen submission required (omissions may cause denial)

    Please submit the complete oncology regimen to Evolent; omission of any regimen components may result in denial of the request.

    • The policy emphasizes submitting the entire regimen regardless of individual prior authorization requirements.
  1. Pharmacy benefit products: Herceptin, Herceptin Hylecta, Herzuma, Kanjinti, Ogivri, Ontruzant, Trazimera.
  2. Billing Rule

    Bevacizumab/Avastin — biosimilar and pharmacy benefit listings

    Preferred medical‑benefit bevacizumab biosimilars include Mvasi and Zirabev; Avastin and the biosimilars Mvasi and Zirabev are listed on the pharmacy benefit.

    • Medical benefit preferred: Mvasi, Zirabev.
    • Pharmacy benefit: Avastin, Mvasi, Zirabev.